A carregar...

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations

Background. According to randomized clinical trial SOLO1 olaparib statistically significantly improves progression-free survival versus placebo as a maintenance monotherapy in patients aged 18 and over with newly diagnosed advanced ovarian cancer with BRCA mutations, who had response to first-line c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, A. S. Makarov
Formato: Artigo
Idioma:Russo
Publicado em: ABV-press 2021-10-01
Colecção:Opuholi Ženskoj Reproduktivnoj Sistemy
Assuntos:
Acesso em linha:https://ojrs.abvpress.ru/ojrs/article/view/868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!